Cargando…

A phase II study of a modified FOLFOX6 regimen as neoadjuvant chemotherapy for locally advanced gastric cancer

BACKGROUND: We evaluated the efficacy and safety of the modified FOLFOX6 (mFOLFOX6) regimen as a neoadjuvant chemotherapy in gastric cancer patients. METHODS: Seventy-three patients with T2–T4 or N+ were enroled. Preoperative chemotherapy consisted of three cycles of mFOLFOX6. The primary end points...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Xiang, Zhao, Lin, Liu, Hongfeng, Zhong, Dingrong, Liu, Wei, Shan, Guangliang, Dong, Fen, Gao, Weisheng, Bai, Chunmei, Li, Xiaoyi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4984457/ https://www.ncbi.nlm.nih.gov/pubmed/27172250 http://dx.doi.org/10.1038/bjc.2016.126

Ejemplares similares

FOLFOX versus EOX as a neoadjuvant chemotherapy regimen for patients with advanced gastric cancer
por: CHEN, WENJUN, et al.
Publicado: (2014)

Complications after radical gastrectomy following FOLFOX7 neoadjuvant chemotherapy for gastric cancer
por: Li, Zi-Yu, et al.
Publicado: (2011)

Adjuvant Chemotherapy Using the FOLFOX Regimen in Colon Cancer
por: Jeon, Hyeong-Joon, et al.
Publicado: (2011)

Neoadjuvant FOLFOX chemotherapy combined with radiotherapy followed by radical resection in patients with locally advanced colon cancer
por: Huang, Chun-Ming, et al.
Publicado: (2017)

Clinical Efficacy of Modified Yiwei Shengyang Decoction Combined with FOLFOX4 Chemotherapy Regimen in the Treatment of Advanced Gastric Cancer and Its Effect on Tumor Marker Levels
por: Wu, Hongying, et al.
Publicado: (2022)

ERCC1 mRNA levels and survival of advanced gastric cancer patients treated with a modified FOLFOX regimen
por: Wei, J, et al.
Publicado: (2008)

Modified FOLFIRI as Second-Line Chemotherapy after Failure of Modified FOLFOX-4 in Advanced Gastric Cancer
por: Jeon, Eun Kyoung, et al.
Publicado: (2011)

Complete pathological response following neoadjuvant FOLFOX chemotherapy in BRCA2-mutant locally advanced rectal cancer: a case report
por: Lin, Zhenyu, et al.
Publicado: (2018)

Neoadjuvant Chemotherapy with FOLFOX4 Regimen to Treat Advanced Gastric Cancer Improves Survival without Increasing Adverse Events: A Retrospective Cohort Study from a Chinese Center
por: Sun, Zhen, et al.
Publicado: (2014)

Neoadjuvant Modified FOLFOX6 With or Without Radiation Versus Fluorouracil Plus Radiation for Locally Advanced Rectal Cancer: Final Results of the Chinese FOWARC Trial
por: Deng, Yanhong, et al.
Publicado: (2019)

SULF2 Methylation Is Associated with In Vitro Cisplatin Sensitivity and Clinical Efficacy for Gastric Cancer Patients Treated with a Modified FOLFOX Regimen
por: Shen, Jie, et al.
Publicado: (2013)

Comparison of FOLFOX and DOF regimens as first-line treatment in East Asian patients with advanced gastric cancer
por: Liu, Mengyao, et al.
Publicado: (2018)

The effect and clinical efficacy of lienal polypeptide injection combined with FOLFOX chemotherapy regimen in colon cancer patients
por: Zhou, Juan, et al.
Publicado: (2016)

Triplet versus doublet neoadjuvant chemotherapy regimens for locally advanced gastric cancer: a propensity score matching analysis
por: Chen, Yonghe, et al.
Publicado: (2021)

Curative resection for locally advanced sigmoid colon cancer using neoadjuvant chemotherapy with FOLFOX plus panitumumab: A case report
por: Tomizawa, Kenji, et al.
Publicado: (2017)

Pathological complete response after neoadjuvant chemotherapy with FOLFOX for locally advanced sigmoid colon cancer with diverticulitis: A case report
por: Asada, Yusuke, et al.
Publicado: (2021)

The validity of neoadjuvant chemotherapy with paclitaxel plus S-1 is not inferior to that of SOX regimen for locally advanced gastric cancer: an observational study
por: Zhang, Chenghai, et al.
Publicado: (2022)

Modified Folfox6 as Adjuvant Chemotherapy in Vietnamese Patients With Colorectal Cancer
por: Nguyen, T. Quang, et al.
Publicado: (2019)

Efficacy of modified FOLFOX6 chemotherapy for patients with unresectable pseudomyxoma peritonei
por: Hiraide, Sakura, et al.
Publicado: (2019)

Two postoperative chemotherapies for gastric cancer: FOLFOX4 vs. TPF
por: Xie, Honghu, et al.
Publicado: (2019)

Evaluation of Pathological Response Rate and Complications of FOLFOX versus FLOT Regimen in Perioperative Chemotherapy for Resectable Gastric Cancer: A Prospective Study
por: Arefpour, Amir Mohammad, et al.
Publicado: (2023)

Efficacy and safety of FLOT regimen vs DCF, FOLFOX, and ECF regimens as perioperative chemotherapy treatments for resectable gastric cancer patients; a report from the middle east
por: Farrokhi, Pegah, et al.
Publicado: (2022)

Comparison the Incidence and Severity of Side Effects Profile Of FOLFOX and DCF Regimens in Gastric Cancer Patients
por: Salehifar, Ebrahim, et al.
Publicado: (2019)

Optimal Timing to Surgery After Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer
por: Wang, Yinkui, et al.
Publicado: (2020)

The efficacy and adverse reactions of DCF and FOLFOXs regimens for patients with advanced gastric cancer in China: a meta-analysis
por: Chen, Minxue, et al.
Publicado: (2020)

Comparisons of Efficacy, Safety, and Cost of Chemotherapy Regimens FOLFOX4 and FOLFIRINOX in Rectal Cancer: A Randomized, Multicenter Study
por: Qi, Fei, et al.
Publicado: (2018)

Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker
por: Keam, Bhumsuk, et al.
Publicado: (2008)

Clinical effects of Apatinib combined with DOS neoadjuvant chemotherapy regimen in neoadjuvant chemotherapy for LAGC
por: Zhou, Peng-zhe, et al.
Publicado: (2021)

Modified FOLFIRINOX versus sequential chemotherapy (FOLFIRI/FOLFOX) as a second‐line treatment regimen for unresectable pancreatic cancer: A real‐world analysis
por: Tezuka, Shun, et al.
Publicado: (2021)

Serum miR-191 and miR-425 as Diagnostic and Prognostic Markers of Advanced Gastric Cancer Can Predict the Sensitivity of FOLFOX Chemotherapy Regimen
por: Bie, Liang-Yu, et al.
Publicado: (2020)

A Huge Sister Mary Joseph’s Nodule From Signet Ring Cell Gastric Carcinoma Showing Good Response to FOLFOX-Based Chemotherapy Regimen
por: Rais, Ghizlane, et al.
Publicado: (2022)

Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer
por: Han, S-W, et al.
Publicado: (2009)

Reply to comments on “Efficacy of modified FOLFOX6 chemotherapy for patients with unresectable pseudomyxoma peritonei”
por: Hiraide, Sakura, et al.
Publicado: (2021)

Treatment Switch in Poor Responders with Locally Advanced Gastric Cancer After Neoadjuvant Chemotherapy
por: Liu, Zining, et al.
Publicado: (2021)

Neoadjuvant Chemotherapy in Asian Patients With Locally Advanced Gastric Cancer
por: Tong, Xie, et al.
Publicado: (2023)

Randomized phase II study comparing the efficacy and safety of SOX versus mFOLFOX6 as neoadjuvant chemotherapy without radiotherapy for locally advanced rectal cancer (KSCC1301)
por: Miwa, Keisuke, et al.
Publicado: (2021)

Efficacy of Neoadjuvant Chemotherapy DOX and XELOX Regimens for Patients with Resectable Gastric or Gastroesophageal Junction Adenocarcinoma
por: Tian, Yuan, et al.
Publicado: (2021)

Platelet-to-lymphocyte ratio and lymphocyte-to-white blood cell ratio predict the efficacy of neoadjuvant chemotherapy and the prognosis of locally advanced gastric cancer patients treated with the oxaliplatin and capecitabine regimen
por: Tang, Cheng, et al.
Publicado: (2018)

The optimal neoadjuvant chemotherapy regimen for locally advanced gastric and gastroesophageal junction adenocarcinoma: a systematic review and Bayesian network meta-analysis
por: Wang, Tongya, et al.
Publicado: (2022)

The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 months) Regimen for Patients with Stage III Colon Cancer: Trial Design and Current Status
por: André, Thierry, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_4leu7gqpus7gvcpe7ric7hahu9